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Neurodevelopmental disorders include conditions like Intellectual Disability, Autistic 
Spectrum Disorders and Attention Deficit Hyperactivity Disorders. In comparison to the 
general population, people with these disorders have higher prevalence of behaviours that 
challenge, psychiatric illnesses and physical health problems. The interface between these 
can be particularly complex. Hence diagnosis and treatment of these conditions require a 
close working relationship between patients, family members and healthcare professionals. 
For that relationship to be effective and deliver good treatment outcomes, these three groups 
should pay particular attention to their respective areas of expertise. The good treatment 
strategies and outcomes that everyone aspires to are also underpinned by robust research 
evidence in basic sciences, clinical practice and service models. While there has been good 
work in this area recently, more needs to be done and the key research priorities are 
highlighted.  
 
Key words: neurodevelopmental disorders, intellectual disability, autism, ADHD, learning 
disability, experts by experience 
 
Neurodevelopmental disorders (NDDs) are conditions that are grouped together because 
they are characterised by some form of disruption to typical brain development. This 
definition would mean that the range of conditions that are included in this group would be 
very wide and disparate. In an approach that provides much greater clinical utility for patients 
and professionals, the Diagnostic Statistical Manual edition five (DSM-5) only includes 
intellectual disabilities (ID), autism spectrum disorder (ASD), Attention Deficit Hyperactivity 
Disorder (ADHD), communication disorders, specific learning disorders and motor disorders 
as part of this group. While heterogeneous, they share some common characteristics: 
childhood onset, a steady rather than remitting and relapsing course, early onset of 
neurocognitive deficits, high heritability indices and a marked overlap between their core 
symptom domains [1]. While their lifetime prevalence varies (1% for ASD, 2% for ID, 2.5% 
for ADHD, etc), NDDs often co-occur and up to 10% of the population may have one 
according to a recently formed coalition of charities in this field 
(https://embracingcomplexity.org.uk). They point out that this often causes problems in 
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accessing help, particularly in countries where services are set up exclusively for one 
disorder and exclude people because they have other co-occurring conditions. 
 
The diagnosis and treatment of mental health difficulties in people with NDDs sometimes 
raises contentious issues. We explore in this editorial some of the key themes starting with 
the interface between ‘behaviour that challenges’ and psychiatric conditions. We then 
discuss the central role of patients and their families (i.e. experts with lived experience), in 
the treatment process, and how that involvement should complement the expertise of health 
professionals (i.e. experts by profession) if good outcomes are to be achieved. Finally, we 
will reflect on how high-quality research is central to the delivery of good treatment outcomes 
and set out some of the key research themes that are currently prioritised. 
 
Behaviour that Challenges and Psychiatric Conditions 
In comparison to the general population, people with NDDs can have higher rates of 
behaviours that challenge (BtC). This may bring them into contact with mental health 
professionals. A socially constructed and descriptive concept often driven by environmental 
factors, BtC is certainly not a psychiatric diagnosis. However, it is worth noting that in 
comparison to the general population, people with NDDs also have higher rates of 
psychiatric morbidity. Some of this psychiatric morbidity may well present with BtC. Indeed, 
the presence of a NDD and the communication difficulties associated with it will affect the 
way in which psychiatric morbidity manifests itself, the modes of treatment and the outcomes 
of treatment. This means that when an individual with an NDD presents with BtC, a careful 
assessment for any co-existing psychiatric or physical health conditions is required.  For 
example, the aetiology of BtC displayed by a previously well-adjusted, middle aged man with 
Down syndrome could be underlying physical health concerns (pain, sensory visual or 
auditory problems, constipation, sleep issues, undiagnosed hypothyroidism), psychological 
issues (depressive or anxiety features, bereavement), cognitive concerns (early onset of 
dementia), environmental stressors, or a combination of them all.  It is this complexity that 
makes the diagnosis and treatment of mental and behavioural disorders in people with 
NDDs a particularly challenging area of psychiatric practice [2]. 
 
Experts with Lived Experience and Experts by Profession 
In such situations, it is important to centre the lived experience of patients and their families 
within all clinical care, and thereby minimise the risk of ‘diagnostic overshadowing’ where the 
presentation is inappropriately explained away by the presence of an NDD. From embedding 
reasonable adjustments to ensure psychiatric services are accessible, to providing 
treatments which are developmentally appropriate, and diligently avoiding restrictive 
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treatment strategies like overmedication with psychotropics or inappropriate psychiatric 
hospitalisation, patients and their families, (experts with lived experience), have an important 
role to play as partners in mental health care [2]. In this regard, it is also important to 
appreciate that the risk is not merely one of restrictive treatments. There is the equally 
unacceptable risk that by formulating everything solely through the prism of lived experience, 
treatable psychiatric conditions may potentially be missed or under-treated. This may well be 
because healthcare professionals come under pressure to avoid the diagnosis of psychiatric 
illness because of an erroneous assumption that the act of diagnosis itself is one of labelling 
that leads to restrictive practice. When this happens, the risk of excess morbidity and 
mortality in people with NDDs can get worse. 
 
To elaborate on this, some of the healthcare professionals who are authors of this editorial 
draw upon their personal experiences with major physical illnesses. The experience of 
having had multiple cardiac arrests and heart failure has made one an expert by lived 
experience, who can give meaningful advice on improving the patient experience in cardiac 
intensive care units, while simultaneously acknowledging that deciding the right treatment for 
cardiac failure does require a different kind of specialist professional expertise. Likewise, 
living through an invasive cancer has allowed another to become an expert on the patient 
experience of the side effects of chemotherapy, while also recognising that this expertise is 
qualitatively different to the specialist knowledge of an oncologist. Yet another, who 
developed problems with chronic pain, can easily articulate the overwhelming and enduring 
feelings of pain so severe that it was impossible to get out of bed, along with the side effects 
of the numerous powerful medications that were prescribed, until collaboratively, using the 
expert knowledge of pain specialists, the most helpful medication was found leading to 
improvements in quality of life.  We surmise from this that the patient is indeed the expert 
with lived experience of the condition; appropriately qualified professionals are the experts in 
terms of the science that underpins diagnosis and treatments, and the two must listen and 
learn from each other. Some say that “the real expert is always the patient”, and this is true, 
but both professionals and patients must avoid positioning themselves upon a polarised 
continuum.  Good care occurs when professionals recognise patient expertise. Recognition 
of professional knowledge in diagnosis and treatment is an equally important component of 
good care, one that will avoid disadvantaging some patient groups. Just as one would never 
expect that disadvantage in cancer or cardiac failure treatment, one should not expect it in 
the field of NDDs and mental health conditions. This is not to say that patients and families 
of people with NDD do not have any expertise in diagnosis or treatment - far from it. Indeed, 
one of the expert by experience authors can draw upon his own experience to demonstrate 
this point well.  There was a situation when he and the rest of the family were quite 
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convinced that their loved one’s challenging behavior was driven in part by an underlying 
mental illness. They knew this because they were the people who were best placed to 
observe and appreciate the nuances of the family member’s clinical presentation. This 
message was not accepted by some professionals. It took the family’s dogged 
perseverance, a new team of professionals committed to working collaboratively with them, 
the safe space of an in-patient unit and a systematic assessment to identify the complex 
diagnostic strands and secure the best treatment outcomes. Likewise, another expert by 
experience has written about how he recorded carefully and perceptively his daughter’s 
clinical presentation as suggestive of depression, but was not listened to appropriately by 
professionals for quite some time. This experience later led to co-produced guidelines on 
improving family experiences of accessing and engaging with mental health/IDD services [2]. 
Suffice to say that if we want equity of treatment outcomes in NDDs as much as equity of 
access to healthcare, then healthcare professionals, patients and family members should 
work collaboratively paying due attention to their respective areas of expertise.   In that way, 
the lived experience of patients and families can effectively and safely complement 
treatment approaches that are informed by scientific knowledge and expertise. In this whole 
process, the importance of professionals sharing information in an accessible format with 
patients and their carers cannot be overemphasised.  
 
Good Treatment Outcomes and Research 
Good treatment outcomes for patients can be achieved only by a good evidence-base and 
high-quality research. For decades, this area has been hampered by a relative paucity in 
relation to basic sciences, clinical practice and service models. This is changing gradually, 
and in the last 6 years there have been a number of National Institute of Healthcare and 
Care Excellence (NICE) clinical guidelines on neurodevelopmental disorders, a development 
indicating a growing evidence base in this area. Key research priorities for people with ID, 
ASD and ADHD, as drawn from the respective NICE guidelines, are summarized in table 1.  
 
(Insert table 1 here). 
 
More recently, a themed review published by the National Institute of Health Research 
(NIHR) Dissemination Centre highlighted 23 NIHR-funded influential studies, many co-
produced by people with intellectual disability and family carers, strengthening our point 
about the importance of professionals and those with lived experience working together 
collaboratively. It set out future research priorities which included health checks, intellectual 
disability services for children, mental wellbeing promotion, mental health self-management 
programmes, supported living outside hospital settings, domestic abuse of women with 
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intellectual disability and reasonable adjustments in general hospitals [3]. There is also a 
need to use routinely collected clinical data in a meaningful way to measure treatment 
outcomes and benchmark services   
 
In addition to these, there have been several other promising new areas of research. 
Genetics is not only providing an understanding of neurodevelopmental conditions, but also 
looking at developing interventional tools [4]. While pharmacogenomics [5] is looking to 
establish itself in giving insights to medication response based on unique individual 
characteristics, efforts to identify and validate biomarkers in various domains are under way.  
Elsewhere, there are enquires into issues such as diet types and the human microbiome 
influence on brain maturation. Technological advances in improving diagnosis, providing bio-
feedback responses and engaging individuals into vocations are being piloted. These 
person-centred approaches for people with neurodevelopmental conditions offer the hope 
that psychiatric and behavioural co-morbidity in this group can be addressed through 
innovative means. In the quest to explore these new frontiers, it is important not to lose sight 
of those simple and effective interventions such as Annual Health Checks which have 
proved to make a positive difference. 
 
References  
[1] Thapar, A, Cooper, M, Rutter, M. Neurodevelopmental disorders. Lancet Psychiatry. 
2017; 4:339–46. 
[2] Oxford University Press. Oxford Textbook of Psychiatry of Intellectual Disability (Ed: S 
Bhaumik, R Alexander). Oxford University Press, 2020  
[3] National Institute for Health Research. Better health and care for all. 
https://content.nihr.ac.uk/nihrdc/themedreview-04326-BCAHFA/Better-Health_Care-For-
FINALWEB.pdf  NIHR Dissemination Centre, February 2020 
[4] Ilaria, P, Luis,G,R, Hanna,S, Gaia,N. Neurodevelopmental Disorders: From Genetics to 
Functional Pathways. Trends Neurosciences. 2020; 43: 608-621 
[5] Cacabelos,R. Pharmacogenomics of drugs used to treat brain disorders, Expert Review 
of Precision Medicine and Drug Development, 2020; 5:3, 181-234 
 
Declaration of Interest: 
None of the authors have any interests to declare in relation to this study. The first 3 authors 
are editors of this special issue, but are not involved in the peer review of this editorial. The 
last author has received institutional and research support and personal fees from UCB, 
Eisai, Bial, Veriton Pharma, GW pharma, Livanova and Desitin outside the submitted work. 
 6 
 
